Skip to content
Review Open access

Toward Precision Neuropsychiatry of Dementia: Neuropsychiatric Symptoms as Multidimensional Clinical Phenotypes

Aug 2026 · Psychogeriatrics · Vol 26 · 0 citations · 62 references
Medicine

TL;DR

A precision neuropsychiatry framework that conceptualises NPS—including apathy, agitation, psychosis, depression, and sleep disturbances—as multidimensional clinical phenotypes is introduced that stratifies NPS based on disease background, clinical stage, neural networks, biological aging, physical vulnerability, and psychosocial context to optimise differential diagnosis, prognostic prediction, and targeted interventions.

Abstract

Neuropsychiatric symptoms (NPS) are the most clinically consequential manifestations of dementia, yet they are frequently underestimated as secondary behavioural complications. This review introduces a precision neuropsychiatry framework that conceptualises NPS—including apathy, agitation, psychosis, depression, and sleep disturbances—as multidimensional clinical phenotypes. These phenotypes bridge neurodegeneration, biological aging, brain network disruption, psychosocial context, functional decline, and caregiver burden. We trace the conceptual evolution from dementia to neurocognitive disorders, and from behavioural and psychological symptoms of dementia (BPSD) to NPS and mild behavioural impairment (MBI). Precision neuropsychiatry stratifies NPS based on disease background, clinical stage, neural networks, biological aging, physical vulnerability, and psychosocial context to optimise differential diagnosis, prognostic prediction, and targeted interventions. Although conventional symptom‐based classification remains practically useful, it must be complemented by biological, functional, and contextual stratification; identical symptom labels often arise from distinct mechanisms and express differently based on personality, life history, environmental mismatch, and available resources. Emerging evidence from MBI, neuroimaging, brain‐age paradigms, frailty, neuroinflammation, Alzheimer's disease (AD) biomarkers, and international consensus criteria supports this multidimensional shift. Future research should advance from cross‐sectional symptom descriptions toward longitudinal, mechanism‐informed, and context‐sensitive models to translate these findings into real‐world psychogeriatric care.

Read PDF

Similar papers

Review Sep 2026

Neuropsychiatric Symptoms in Primary Progressive Aphasia: Phenomenology, Circuits, and Clinical Management

This review synthesizes evidence on the phenomenology, neurobiology, assessment, and treatment of neuropsychiatric symptoms in primary progressive aphasia with emphasis on variant-specific patterns and consequences, and decides whether neuropsychiatric features should be incorporated into revised PPA diagnostic criteri...

D. Vilella, Alessandra Vitulli, Eleonora Rollo et al. · 0 citations
Review Open access Sep 2026

Integrated approaches to geriatric mental disorders: pathophysiology, interventions, and precision medicine horizons

This review synthesizes current evidence on the unique pathophysiology, clinical management, and emerging frontiers of geriatric mental health, emphasizing the interplay of neurobiological aging, multimorbidity, and psychosocial stressors to advance precision psychiatry for LMDs.

Jin Wang, An-Qi Li · 0 citations
Open access Oct 2026

A-02: Neuropsychiatric Symptoms Predict Functional Disability Across Parkinsonian Disorders

Objective: Neuropsychiatric symptoms (NPS) are common across parkinsonian disorders. Symptom profiles vary by diagnosis and stage of disease, and individual symptoms may differentially affect everyday functioning. We evaluated the impact of NPS on functional status in Parkinson’s disease (PD), Lewy body disease (LBD)...

Andrea Collins, Jordan Kozuki, Lily Wilkin et al. · 0 citations
Review Open access Sep 2026

Neurobiological mechanisms and brain network dysfunction in major depressive disorder: an integrative review

Major depressive disorder (MDD) is a prevalent and disabling psychiatric disorder characterized by persistent mood disturbances, cognitive impairments, and significant systemic consequences. Despite its substantial clinical burden, diagnosis remains challenging because current approaches rely largely on subjective symp...

D. Iskakova, Burcu Yener, A. Kamzanova et al. · 0 citations
#federated learning Open access Sep 2026

Artificial Intelligence in Dementia with Lewy Bodies — Current Applications, Diagnostic Challenges, and Future Perspectives

Multiodal biomarker studies in mild cognitive impairment with Lewy bodies have suggested that combinations of MRI, EEG, and plasma markers may provide additional prognostic information beyond cognitive testing alone, but these findings should not be interpreted as evidence that AI is ready for autonomous clinical diagn...

Maria Ciubotaru, Laura Romila, A. Ciobîcă et al. · 0 citations
Review Oct 2026

[Mild cognitive impairment as a heterogeneous condition: From diagnostic algorithm - to individualized therapeutic approaches].

Mild cognitive impairment (MCI) is a prevalent syndrome affecting approximately 10-15% of the global population. In the Russian Federation, the estimated number of individuals with MCI may reach 5 million, with continued growth projected. Subjective cognitive deficits are linked to an increased risk of dementia, althou...

E. Vasenina · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.